Mastoid Osteoma of Temporal Bone – A Rare Case Report
Journal Title: Journal of Clinical and Diagnostic Research - Year 2017, Vol 11, Issue 6
Abstract
Osteomas of the temporal bone are rare entity with incidence of 0.1% - 1% of all benign tumours of skull. They are slow growing benign lesion of temporal bone. We report a rare case of mastoid osteoma of size more than 5 cm. A 40-year-old female patient presented to us with left post auricular bony swelling of size greater than 5 cm. Diagnosis of mastoid osteoma was made after relevant investigations including High Resolution Computed Tomography (HRCT) temporal bone. Complete surgical excision was done with good cosmetic outcome without recurrence.
Authors and Affiliations
RAHUL KUMAR SINGH, AMIT GOYAL, GAURAV KATARIA, AMBER KESARWANI
Jategaonkar’s Modification of Brooke’s End-Ileostomy
Letter to Editor
Osseous Metaplasia in Adenocarcinoma
ABSTRACT Osseous Metaplasia (OM) or heterotopic ossification is a rare phenomenon with unknown aetiology that is characterised by the formation of mature bone elements in the stroma of different tumors. Awareness of this...
Surgical Outcome of Epicanthus and Telecanthus Correction by Double Z-Plasty and Trans-Nasal Fixation with Prolene Suture in Blepharophimosis Syndrome
Introduction: Blepharophimosis Syndrome (BPES) is a complex and rare disease characterized by epicanthus inversus, telecanthus, lateral ectropion, narrowed or shortened interpalpebral fissure distance and ptosis. It is m...
Various Clinical and Histopathological Patterns of Idiopathic Photodermatosis: An Observational Study
ABSTRACT Introduction: The idiopathic photodermatosis have different histopathological patterns, spongiotic pattern being the most common. Aim: To study the histopathological patterns of photodermatosis and to correlate...
Inhaled Insulin - Current Direction of Insulin Research
Diabetes Mellitus (DM) is a metabolic disorder characterized by relative or absolute deficiency of insulin, resulting in hyperglycemia. Subcutaneous insulin and Oral Hypoglycaemic Agents (OHA) constitute the main treatme...